Oncología Médica Traslacional y Terapia Individualizada del Cáncer

García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S.

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF(V600E)-mutant metastatic and/or unresectable colorectal cancer.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 173: 103646-103646 Nº de citas: 7 [doi:10.1016/j.critrevonc.2022.103646]

van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

EUROPEAN JOURNAL OF CANCER. 2022; 166: 185-201 Nº de citas: 9 [doi:10.1016/j.ejca.2022.02.003]

Cortese, S; Peligros, MI; Sola, E; Garcia-Alfonso, P; Tellado, JM.

Indocyanine green clearance test as a predictor of chemotherapy liver toxicity and post-operative complications in patients with colorectal liver metastases

CIRUGIA Y CIRUJANOS. 2022; 90(3): 310-318 Nº de citas: 1 [doi:10.24875/CIRU.21000313]

Lee, RJ; Wysocki, O; Zhou, C; Shotton, R; Tivey, A; Lever, L; Woodcock, J; Albiges, L; Angelakas, A; Arnold, D; Aung, T; Banfill, K; Baxter, M; Barlesi, F; Bayle, A; Besse, B; Bhogal, T; Boyce, H; Britton, F; Calles, A; Castelo-Branco, L; Copson, E; Croitoru, AE; Dani, SS; Dickens, E; Eastlake, L; Fitzpatrick, P; Foulon, S; Frederiksen, H; Frost, H; Ganatra, S; Gennatas, S; Glenthoj, A; Gomes, F; Graham, DM; Hague, C; Harrington, K; Harrison, M; Horsley, L; Hoskins, R; Huddar, P; Hudson, Z; Jakobsen, LH; Joharatnam-Hogan, N; Khan, S; Khan, UT; Khan, K; Massard, C; Maynard, A; McKenzie, H; Michielin, O; Mosenthal, AC; Obispo, B; Patel, R; Pentheroudakis, G; Peters, S; Rieger-Christ, K; Robinson, T; Rogado, J; Romano, E; Rowe, M; Sekacheva, M; Sheehan, R; Stevenson, J; Stockdale, A; Thomas, A; Turtle, L; Vinal, D; Weaver, J; Williams, S; Wilson, C; Palmieri, C; Landers, D; Cooksley, T; Dive, C; Freitas, A; Armstrong, AC.

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Jco Clinical Cancer Informatics. 2022; 6: Nº de citas: 4 [doi:10.1200/CCI.21.00177]

Benavides, M; Gomez-Espana, A; Garcia-Alfonso, P; Gonzalez, CG; Vieitez, JM; Rivera, F; Safont, MJ; Abad, A; Sastre, J; Valladares-Ayerbes, M; Carrato, A; Gonzalez-Flores, E; Robles, L; Salud, A; Alonso-Orduna, V; Montagut, C; Asensio, E; Diaz-Rubio, E; Aranda, E.

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

EJSO. 2022; 48(5): 1123-1132 Nº de citas: 4 [doi:10.1016/j.ejso.2021.11.122]

Peddi, PF; Fasching, PA; Liu, D; Quinaux, E; Robert, NJ; Valero, V; Crown, J; Falkson, C; Brufsky, A; Cunningham, JM; Weinshilboum, RM; Pienkowski, T; Eiermann, W; Martin, M; Bee, V; Wang, XY; Wang, LW; Yang, ER; Slamon, DJ; Hurvitz, SA.

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

CLINICAL CANCER RESEARCH. 2022; 28(9): 1854-1862 Nº de citas: 8 [doi:10.1158/1078-0432.CCR-21-1762]

Campone, M; De Laurentiis, M; Zamagni, C; Kudryavcev, I; Agterof, M; Brown-Glaberman, U; Palacova, M; Chatterjee, S; Menon-Singh, L; Wu, JW; Martin, M.

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

BREAST CANCER RESEARCH AND TREATMENT. 2022; 193(1): 95-103 Nº de citas: 7 [doi:10.1007/s10549-022-06543-1]

Agnelli, G; Munoz, A; Franco, L; Mahe, I; Brenner, B; Connors, JM; Gussoni, G; Hamulyak, EN; Lambert, C; Suero, MR; Bauersachs, R; Torbicki, A; Becattini, C.

Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

THROMBOSIS AND HAEMOSTASIS. 2022; 122(05): 796-807 Nº de citas: 37 [doi:10.1055/s-0041-1735194]

Cottu, P; Ring, A; Abdel-Razeq, H; Marchetti, P; Cardoso, F; Bofill, JS; Martin, M; Menon-Singh, L; Wu, JW; De Laurentiis, M.

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

BREAST. 2022; 62: 75-83 Nº de citas: 8 [doi:10.1016/j.breast.2022.01.016]

Duca, M; Lim, DWT; Subbiah, V; Takahashi, S; Sarantopoulos, J; Varga, A; D'Alessio, JA; Abrams, T; Sheng, Q; Tan, EY; Rosa, MS; Gonzalez-Maffe, J; Sand-Dejmek, J; Fabre, C; Martin, M.

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

MOLECULAR CANCER THERAPEUTICS. 2022; 21(4): 625-634 Nº de citas: 5 [doi:10.1158/1535-7163.MCT-21-0652]

Verso, M; Agnelli, G; Munoz, A; Connors, JM; Sanchez, O; Huisman, M; Brenner, B; Gussoni, G; Cohen, AT; Becattini, C.

Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

EUROPEAN JOURNAL OF CANCER. 2022; 165: 136-145 Nº de citas: 10 [doi:10.1016/j.ejca.2022.01.023]

Blum, JL; Laird, AD; Litton, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Martin, M; Roche, HH; Lee, KH; Goodwin, A; Chen, Y; Lanzalone, S; Chelliserry, J; Czibere, A; Hopkins, JF; Albacker, LA; Mina, LA.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

CLINICAL CANCER RESEARCH. 2022; 28(7): 1383-1390 Nº de citas: 12 [doi:10.1158/1078-0432.CCR-21-2080]

Valderrama, BP; Gonzalez-del-Alba, A; Morales-Barrera, R; Fernandez, IP; Vazquez, S; Diaz, CC; Domenech, M; Calvo, OF; Lista, AGD; Arija, JAA.

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 613-624 Nº de citas: 9 [doi:10.1007/s12094-022-02815-w]

Majem, M; de las Penas, R; Virizuela, JA; Cabezon-Gutierrez, L; Cruz, P; Lopez-Castro, R; Mendez, M; Mondejar, R; Munoz, MD; Escobar, Y.

SEOM clinical guideline emesis (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 712-723 Nº de citas: 6 [doi:10.1007/s12094-022-02802-1]

Felip, E; Moreno, V; Morgensztern, D; Curigliano, G; Rutkowski, P; Trigo, JM; Calvo, A; Kowalski, D; Cortinovis, D; Plummer, R; Maio, M; Ascierto, PA; Vladimirov, VI; Cervantes, A; Zudaire, E; Hazra, A; T'jollyn, H; Bandyopadhyay, N; Greger, JG; Attiyeh, E; Xie, H; Calvo, E.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2022; 89(4): 499-514 Nº de citas: 7 [doi:10.1007/s00280-022-04414-6]

Echavarria, I; Galindo, JRC; Corral, J; Tain, MPD; Carrasco, FH; Gonzalez-Cruz, VI; Mielgo-Rubio, X; Quintanar, T; Corredor, CR; Segura, PP.

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 724-732 Nº de citas: 9 [doi:10.1007/s12094-022-02800-3]

Elez, E; Gomez-Espana, MA; Gravalos, C; Garcia-Alfonso, P; Ortiz-Morales, MJ; Losa, F; Diaz, IA; Grana, B; Toledano-Fonseca, M; Valladares-Ayerbes, M; Polo, E; Salgado, M; De Castro, EM; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, J; Riesco, MD; Rodriguez-Ariza, A; Aranda, E.

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

BRITISH JOURNAL OF CANCER. 2022; 126(6): 874-880 Nº de citas: 5 [doi:10.1038/s41416-021-01638-w]

Garcia-Saenz, JA; Martinez-Janez, N; Cubedo, R; Jerez, Y; Lahuerta, A; Gonzalez-Santiago, S; Ferrer, N; Ramos, M; Alonso-Romero, JL; Anton, A; Carrasco, E; Chen, JJ; Neuwirth, R; Galinsky, K; Vincent, S; Leonard, EJ; Slamon, D.

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

CLINICAL CANCER RESEARCH. 2022; 28(6): 1107-1116 Nº de citas: 9 [doi:10.1158/1078-0432.CCR-21-2652]